Jason Mills - Penumbra Executive Strategy
| PEN Stock | USD 244.12 0.03 0.01% |
Executive
Jason Mills is Executive Strategy of Penumbra
| Address | One Penumbra Place, Alameda, CA, United States, 94502 |
| Phone | 510 748 3200 |
| Web | https://www.penumbrainc.com |
Jason Mills Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jason Mills against Penumbra stock is an integral part of due diligence when investing in Penumbra. Jason Mills insider activity provides valuable insight into whether Penumbra is net buyers or sellers over its current business cycle. Note, Penumbra insiders must abide by specific rules, including filing SEC forms every time they buy or sell Penumbra'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jason Mills over two months ago Disposition of 770 shares by Jason Mills of Expensify subject to Rule 16b-3 |
Penumbra Management Efficiency
The company has Return on Asset of 0.0333 % which means that on every $100 spent on assets, it made $0.0333 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0313 %, implying that it generated $0.0313 on every 100 dollars invested. Penumbra's management efficiency ratios could be used to measure how well Penumbra manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to grow to 0.07. Also, Return On Capital Employed is likely to grow to 0.06. At this time, Penumbra's Return On Assets are very stable compared to the past year. As of the 1st of December 2024, Asset Turnover is likely to grow to 0.88, while Other Assets are likely to drop about 47.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Katrina JD | Bioventus | 62 | |
| Aimee Einstein | Si Bone | N/A | |
| Joel Batts | Orthopediatrics Corp | N/A | |
| Jon Shear | Nevro Corp | N/A | |
| Thomas MBA | Profound Medical Corp | N/A | |
| Dylan John | Neuropace | N/A | |
| Abbey Goodman | Profound Medical Corp | 41 | |
| David Crawford | Bioventus | N/A | |
| Frank Vizesi | Orthofix Medical | N/A | |
| Suzanne Armstrong | Orthofix Medical | N/A | |
| Irene Thomas | Neuropace | 55 | |
| Michael JD | Si Bone | 46 | |
| Daniel JD | Orthopediatrics Corp | 54 | |
| Niamh Pellegrini | Nevro Corp | 57 | |
| Julie Andrews | Orthofix Medical | 53 | |
| Mathieu Burtnyk | Profound Medical Corp | 42 | |
| MBA BS | Bioventus | N/A | |
| Julie Dewey | Orthofix Medical | 63 | |
| Helen Leupold | Bioventus | N/A | |
| Christofer Christoforou | Nevro Corp | 54 | |
| Daniel Cher | Si Bone | 59 | |
Management Performance
| Return On Equity | 0.0313 | ||||
| Return On Asset | 0.0333 |
Penumbra Leadership Team
Elected by the shareholders, the Penumbra's board of directors comprises two types of representatives: Penumbra inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Penumbra. The board's role is to monitor Penumbra's management team and ensure that shareholders' interests are well served. Penumbra's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Penumbra's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ben Tompkins, Executive Development | ||
| Surbhi Sarna, Independent Director | ||
| Bridget ORourke, Independent Director | ||
| Adam Elsesser, Chairman of the Board, Chief Executive Officer | ||
| James Pray, President International | ||
| Shruthi Narayan, Executive Interventional | ||
| Gita Barry, President Healthcare | ||
| Holly Sit, Director Development | ||
| Lynn Rothman, Executive Vice President, Chief Business Officer | ||
| Arani MD, CoFounder Director | ||
| Pankaj Tiwari, Executive Officer | ||
| Harpreet Grewal, Independent Director | ||
| Maggie Yuen, Chief Financial Officer | ||
| Jee HamlynHarris, Investor Officer | ||
| Don Kassing, Presiding Independent Director | ||
| Adam JD, Chairman, CoFounder | ||
| Ben Sorci, Executive Operations | ||
| Lambert Shiu, Chief Accounting Officer | ||
| Johanna Roberts, Executive Vice President General Counsel, Secretary | ||
| MD FSIR, Chief Officer | ||
| Jason Mills, Executive Strategy | ||
| Thomas Wilder, Independent Director | ||
| Sandra Lesenfants, President Interventional | ||
| Arani Bose, Executive Director and Chief Innovator | ||
| Johanna JD, General VP | ||
| Janet Leeds, Lead Independent Director |
Penumbra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Penumbra a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0313 | ||||
| Return On Asset | 0.0333 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 9.3 B | ||||
| Shares Outstanding | 38.38 M | ||||
| Shares Owned By Insiders | 3.86 % | ||||
| Shares Owned By Institutions | 93.62 % | ||||
| Number Of Shares Shorted | 1.92 M | ||||
| Price To Earning | 191.13 X |
Pair Trading with Penumbra
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Penumbra position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Penumbra will appreciate offsetting losses from the drop in the long position's value.Moving together with Penumbra Stock
Moving against Penumbra Stock
| 0.92 | EKSO | Ekso Bionics Holdings | PairCorr |
| 0.72 | VERO | Venus Concept | PairCorr |
| 0.59 | CI | Cigna Corp | PairCorr |
| 0.53 | DRIO | DarioHealth Corp | PairCorr |
The ability to find closely correlated positions to Penumbra could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Penumbra when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Penumbra - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Penumbra to buy it.
The correlation of Penumbra is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Penumbra moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Penumbra moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Penumbra can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Penumbra. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Penumbra Stock, please use our How to Invest in Penumbra guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Penumbra. If investors know Penumbra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Penumbra listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.261 | Earnings Share 0.88 | Revenue Per Share 30.081 | Quarterly Revenue Growth 0.111 | Return On Assets 0.0333 |
The market value of Penumbra is measured differently than its book value, which is the value of Penumbra that is recorded on the company's balance sheet. Investors also form their own opinion of Penumbra's value that differs from its market value or its book value, called intrinsic value, which is Penumbra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Penumbra's market value can be influenced by many factors that don't directly affect Penumbra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Penumbra's value and its price as these two are different measures arrived at by different means. Investors typically determine if Penumbra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Penumbra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.